Fri Aug 4 16:36:36 2006
Complete replication of hepatitis C virus in cell culture
Lindenbach BD, Evans MJ, Syder AJ, et al.
SCIENCE 309 (5734): 623-626 JUL 22 2005
and the citing papers
stopwords, and 2-character and smaller words are excluded, Word count: 639, All words count: 954
Grand TLCS: 116, Grand TGCS: 195| View: Overview | Sorted by GCS. |
Page 1 of 2: [ 1 2 ]
| # | Word | Pubs | TLCS | TGCS
|
|---|
| 1 | HEPATITIS | 56 | 114 | 191
|
| 2 | VIRUS | 47 | 108 | 165
|
| 3 | REPLICATION | 12 | 83 | 95
|
| 4 | CELL | 10 | 78 | 79
|
| 5 | CULTURE | 4 | 76 | 77
|
| 6 | COMPLETE | 1 | 74 | 74
|
| 7 | ANTIVIRAL | 7 | 6 | 42
|
| 8 | PROTEIN | 5 | 6 | 42
|
| 9 | ADAPTOR | 1 | 6 | 41
|
| 10 | CARDIF | 1 | 6 | 41
|
| 11 | PATHWAY | 1 | 6 | 41
|
| 12 | RIG-I | 1 | 6 | 41
|
| 13 | TARGETED | 1 | 6 | 41
|
| 14 | MECHANISM | 3 | 4 | 18
|
| 15 | RIBAVIRIN | 4 | 4 | 18
|
| 16 | INTERFERON | 4 | 4 | 16
|
| 17 | ACTION | 2 | 3 | 15
|
| 18 | FUNCTION | 2 | 7 | 15
|
| 19 | GENOME | 2 | 7 | 15
|
| 20 | TREATMENT | 1 | 3 | 15
|
| 21 | UNRAVELLING | 1 | 7 | 15
|
| 22 | INFECTIOUS | 7 | 7 | 9
|
| 23 | INTERACTIONS | 2 | 3 | 9
|
| 24 | UNSCRAMBLING | 1 | 3 | 9
|
| 25 | VIRUS-HOST | 1 | 3 | 9
|
| 26 | ACTIVATION | 4 | 5 | 6
|
| 27 | PROSPECTS | 1 | 1 | 6
|
| 28 | VACCINE | 1 | 1 | 6
|
| 29 | ENTRY | 6 | 5 | 5
|
| 30 | GLYCOPROTEINS | 2 | 4 | 5
|
| # | Word | Pubs | TLCS | TGCS
|
|---|
| 31 | PRODUCTION | 3 | 4 | 5
|
| 32 | ANALYSIS | 3 | 1 | 4
|
| 33 | CELLS | 8 | 4 | 4
|
| 34 | COMPLEX | 1 | 1 | 4
|
| 35 | HEPATOMA | 4 | 4 | 4
|
| 36 | HUMAN | 8 | 4 | 4
|
| 37 | LOW-PH-TRIGGERED | 1 | 4 | 4
|
| 38 | QUANTITATIVE | 2 | 1 | 4
|
| 39 | TEMPERATURE-DEPENDENT | 1 | 4 | 4
|
| 40 | TIME-AND | 1 | 4 | 4
|
| 41 | VIVO | 3 | 2 | 4
|
| 42 | EFFECTS | 3 | 1 | 3
|
| 43 | FUSION | 2 | 3 | 3
|
| 44 | HCV | 6 | 2 | 3
|
| 45 | INHIBITS | 3 | 2 | 3
|
| 46 | LIPOSOMES | 1 | 3 | 3
|
| 47 | LOW | 1 | 3 | 3
|
| 48 | MEDIATE | 2 | 3 | 3
|
| 49 | MEMBRANE | 1 | 3 | 3
|
| 50 | PH-DEPENDENT | 1 | 3 | 3
|
| 51 | APOPTOSIS | 1 | 1 | 2
|
| 52 | ASSEMBLY | 2 | 1 | 2
|
| 53 | CDNA-TRANSFECTED | 1 | 2 | 2
|
| 54 | CIRCLE | 1 | 1 | 2
|
| 55 | CONCOMITANT | 1 | 1 | 2
|
| 56 | COUNTERS | 1 | 0 | 2
|
| 57 | CULTURE-GROWN | 1 | 2 | 2
|
| 58 | DISORDERS | 2 | 1 | 2
|
| 59 | FULL | 1 | 1 | 2
|
| 60 | FUNCTIONAL | 2 | 1 | 2
|
| # | Word | Pubs | TLCS | TGCS
|
|---|
| 61 | IMMUNITY | 1 | 0 | 2
|
| 62 | INCORPORATION | 1 | 1 | 2
|
| 63 | INNATE | 2 | 0 | 2
|
| 64 | INTERFERING | 1 | 0 | 2
|
| 65 | INTERFERONS | 1 | 0 | 2
|
| 66 | INTRACELLULARLY | 1 | 1 | 2
|
| 67 | LYMPHOCYTE | 1 | 1 | 2
|
| 68 | LYMPHOCYTES | 1 | 1 | 2
|
| 69 | MUTAGENIC | 1 | 0 | 2
|
| 70 | NAIVE | 1 | 1 | 2
|
| 71 | OCCURS | 1 | 1 | 2
|
| 72 | PATHOGENETIC | 1 | 1 | 2
|
| 73 | PSEUDOPARTICLES | 1 | 1 | 2
|
| 74 | RECOMBINANT | 2 | 1 | 2
|
| 75 | RECULTURED | 1 | 2 | 2
|
| 76 | REQUIRES | 1 | 1 | 2
|
| 77 | RNA | 9 | 1 | 2
|
| 78 | ROBUST | 1 | 2 | 2
|
| 79 | STABLY | 1 | 2 | 2
|
| 80 | SYSTEM | 2 | 2 | 2
|
| 81 | TISSUE | 1 | 1 | 2
|
| 82 | VIRUS-ASSOCIATED | 1 | 1 | 2
|
| 83 | VITRO | 2 | 2 | 2
|
| 84 | ADVANCES | 1 | 0 | 1
|
| 85 | ANTI-HEPATITIS | 1 | 1 | 1
|
| 86 | BIOLOGICAL | 2 | 0 | 1
|
| 87 | CLINICAL | 1 | 0 | 1
|
| 88 | CONFLUENCE-BASED | 1 | 0 | 1
|
| 89 | CULTURED | 1 | 1 | 1
|
| 90 | DETECTION | 1 | 1 | 1
|
| # | Word | Pubs | TLCS | TGCS
|
|---|
| 91 | DEVELOPMENT | 1 | 0 | 1
|
| 92 | DRUG | 1 | 0 | 1
|
| 93 | EFFECT | 3 | 0 | 1
|
| 94 | EFFICIENTLY | 1 | 1 | 1
|
| 95 | EXPRESSION | 4 | 0 | 1
|
| 96 | FACE | 1 | 0 | 1
|
| 97 | FEATURES | 1 | 1 | 1
|
| 98 | FUTURE | 1 | 0 | 1
|
| 99 | GENOTYPE | 1 | 1 | 1
|
| 100 | GROWTH | 1 | 0 | 1
|
| 101 | HIGHLY | 1 | 1 | 1
|
| 102 | HUTCHINSON | 1 | 1 | 1
|
| 103 | INHIBITION | 2 | 0 | 1
|
| 104 | INHIBITOR | 5 | 1 | 1
|
| 105 | LIPOPROTEIN | 2 | 1 | 1
|
| 106 | LOCALIZATION | 1 | 1 | 1
|
| 107 | LOW-DENSITY | 1 | 1 | 1
|
| 108 | MOLECULAR | 3 | 1 | 1
|
| 109 | NOVEL | 4 | 1 | 1
|
| 110 | OXIDIZED | 1 | 1 | 1
|
| 111 | PESTIVIRUS | 1 | 1 | 1
|
| 112 | POLYMERASE | 2 | 1 | 1
|
| 113 | PRACTICE | 1 | 0 | 1
|
| 114 | PROTEINS | 3 | 1 | 1
|
| 115 | RECENT | 1 | 0 | 1
|
| 116 | REPLICATES | 1 | 1 | 1
|
| 117 | REPLICON | 4 | 1 | 1
|
| 118 | REVEALED | 1 | 1 | 1
|
| 119 | RNA-DEPENDENT | 1 | 1 | 1
|
| 120 | SALIENT | 1 | 1 | 1
|
| # | Word | Pubs | TLCS | TGCS
|
|---|
| 121 | SELECTIVE | 1 | 1 | 1
|
| 122 | SENSITIVE | 1 | 1 | 1
|
| 123 | STRAIN | 2 | 1 | 1
|
| 124 | STRUCTURAL | 1 | 1 | 1
|
| 125 | SUBCELLULAR | 1 | 1 | 1
|
| 126 | TARGETS | 2 | 1 | 1
|
| 127 | TRANSLATION | 1 | 0 | 1
|
| 128 | VIRAL | 5 | 1 | 1
|
| 129 | VIROLOGIC | 1 | 0 | 1
|
| 130 | ABUSE | 1 | 0 | 0
|
| 131 | ACHILLES | 1 | 0 | 0
|
| 132 | ACRIDONES | 1 | 0 | 0
|
| 133 | ACTIVITIES | 1 | 0 | 0
|
| 134 | ACTIVITY | 3 | 0 | 0
|
| 135 | ADAPTIVE | 1 | 0 | 0
|
| 136 | AGENTS | 1 | 0 | 0
|
| 137 | ALPHA | 1 | 0 | 0
|
| 138 | ALPHA-GLUCOSIDASE | 1 | 0 | 0
|
| 139 | ANALYSES | 1 | 0 | 0
|
| 140 | ANTI-BVDV | 1 | 0 | 0
|
| 141 | ANTI-HCV | 1 | 0 | 0
|
| 142 | ANTIBODIES | 1 | 0 | 0
|
| 143 | ANTIBODY | 1 | 0 | 0
|
| 144 | APOB-CONTAINING | 1 | 0 | 0
|
| 145 | APOLIPOPROTEIN | 1 | 0 | 0
|
| 146 | APPROACH | 1 | 0 | 0
|
| 147 | APPROACHES | 1 | 0 | 0
|
| 148 | ASSAY | 1 | 0 | 0
|
| 149 | BACULOVIRUS | 1 | 0 | 0
|
| 150 | BILIARY | 1 | 0 | 0
|
| # | Word | Pubs | TLCS | TGCS
|
|---|
| 151 | BINDING | 2 | 0 | 0
|
| 152 | BROADLY | 1 | 0 | 0
|
| 153 | CAPTURING | 1 | 0 | 0
|
| 154 | CARCINOMA | 1 | 0 | 0
|
| 155 | CELL-CELL | 1 | 0 | 0
|
| 156 | CHARACTERIZATION | 4 | 0 | 0
|
| 157 | CHIMERAS | 1 | 0 | 0
|
| 158 | CHRONIC | 1 | 0 | 0
|
| 159 | CLA | 1 | 0 | 0
|
| 160 | CLATHRIN-MEDIATED | 1 | 0 | 0
|
| 161 | CLEAVAGE | 2 | 0 | 0
|
| 162 | COMBINATION | 1 | 0 | 0
|
| 163 | CONSTRUCTION | 1 | 0 | 0
|
| 164 | CORE | 1 | 0 | 0
|
| 165 | CORE-RNA | 1 | 0 | 0
|
| 166 | CULTURES | 1 | 0 | 0
|
| 167 | CYCLOSPORIN | 1 | 0 | 0
|
| 168 | CYCLOSPORINE | 1 | 0 | 0
|
| 169 | CYTOSKELETON | 1 | 0 | 0
|
| 170 | DC-SIGN | 1 | 0 | 0
|
| 171 | DC-SIGNR | 1 | 0 | 0
|
| 172 | DEBIO | 1 | 0 | 0
|
| 173 | DEFINED | 1 | 0 | 0
|
| 174 | DELETION | 1 | 0 | 0
|
| 175 | DENSITY | 1 | 0 | 0
|
| 176 | DEPENDS | 1 | 0 | 0
|
| 177 | DIFFERENT | 2 | 0 | 0
|
| 178 | DIHYDROXY-4-CARBOXYPYRIMIDINES | 1 | 0 | 0
|
| 179 | DIMERIZATION | 1 | 0 | 0
|
| 180 | DIRECT | 1 | 0 | 0
|
| # | Word | Pubs | TLCS | TGCS
|
|---|
| 181 | DISCOVERY | 2 | 0 | 0
|
| 182 | DISPENSABLE | 1 | 0 | 0
|
| 183 | DISTINCT | 3 | 0 | 0
|
| 184 | DIVERSE | 1 | 0 | 0
|
| 185 | DOMAINS | 1 | 0 | 0
|
| 186 | DSRNA-INDUCED | 1 | 0 | 0
|
| 187 | EARLY | 1 | 0 | 0
|
| 188 | EMPIRICISM | 1 | 0 | 0
|
| 189 | ENDOCYTOSIS | 1 | 0 | 0
|
| 190 | ENDOTHELIAL | 1 | 0 | 0
|
| 191 | ENDOTHELIUM | 1 | 0 | 0
|
| 192 | ENGAGEMENT | 1 | 0 | 0
|
| 193 | ENHANCES | 1 | 0 | 0
|
| 194 | ENVELOPE | 1 | 0 | 0
|
| 195 | EPITOPE | 1 | 0 | 0
|
| 196 | ERADICATION | 1 | 0 | 0
|
| 197 | ESCAPE | 1 | 0 | 0
|
| 198 | EXHIBITS | 1 | 0 | 0
|
| 199 | FULLY | 1 | 0 | 0
|
| 200 | FUNCTIONS | 1 | 0 | 0
|
Page 1 of 2: [ 1 2 ]